EDP Sciences logo
Submit your paper
Search
Menu
Home All issues Volume 31 / No 4 (2025) J Oral Med Oral Surg, 31 4 (2025) 36 References
Open Access
Issue
J Oral Med Oral Surg
Volume 31, Number 4, 2025
Article Number 36
Number of page(s) 7
DOI https://doi.org/10.1051/mbcb/2025039
Published online 09 December 2025
  1. Fiche d’information — Dernières statistiques sur l’état de l’épidémie de sida | UNAIDS [Internet. [cité 19 mars 2025]. Disponible sur: https://www.unaids.org/fr/resources/fact-sheet. [Google Scholar]
  2. Rapport Indicateurs de prise en charge des PVVIH dans les COREVIH en France en 2021 [Internet]. [cité 20 mars 2025]. Disponible sur: https://www.corevih-idfnord.fr/wp-content/uploads/2023/03/Rapport-Indicateurs-de-prise-en-charge-des-PVVIH-dans-les-COREVIH-en-France-en-2021.pdf. [Google Scholar]
  3. Lanoy E, Spano J, Bonnet F, Guiguet M, Boué F, Cadranel J, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. Int J Cancer 2011;129:467–475. [Google Scholar]
  4. Étude Ifop pour AIDES : «1984-2024 : La sérophobie en France et les représentations du VIH» [Internet. [cité 19 mars 2025]. Disponible sur: http://www.aides.org/communique/etude-2024-aides-ifop. [Google Scholar]
  5. Pinet V, Lambert C, Goncalves É, Jacomet C, Devoize L. Access to dental care is still complex in 2022 for patients living with HIV despite the need for careful monitoring of pathologies of the oral mucosa. Results of a monocentric cross-sectional study in the Infectious Diseases Department of Clermont-Ferrand University Hospital. Clin Oral Investig 2023, 28: 57. [Google Scholar]
  6. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Clin Infect Dis 1993;17:802–810. [Google Scholar]
  7. Shiboski CH, Patton LL, Webster-Cyriaque JY, Greenspan D, Traboulsi RS, Ghannoum M, et al. The oral HIV/AIDS research alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med 2009;38:481–488. [Google Scholar]
  8. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. Okulicz JF, éditeur. PLoS ONE 2013; 8:e81355. [Google Scholar]
  9. De Almeida VL, Lima IFP, Ziegelmann PK, Paranhos LR, De Matos FR. Impact of highly active antiretroviral therapy on the prevalence of oral lesions in HIV-positive patients: a systematic review and meta-analysis. Int J Oral Maxillofac Surg 2017;46:1497–1504. [Google Scholar]
  10. Palmer G, Robinson P, Challacombe S, Birnbaum W, Croser D, Erridge P, et al. Aetiological factors for oral manifestations of HIV. Oral Dis 1996;2:193–197. [Google Scholar]
  11. Cazein F, Pinget R, Lot F, Pillonel J, Le Strat Y, Sommen C, et al. Découvertes de séropositivité VIH et SIDA – France, 2003-2013. Bull Epidemiol Hebd 2013: 151–162. Disponible sur : https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-sexuellement-transmissibles/vih-sida/documents/article/decouvertes-de-seropositivite-vih-et-de-sida-france-2003-2013. [consulté le 24 mars 2025]. [Google Scholar]
  12. Gaborit B, Lavergne R-A, Morio F, Boutoille D. Infections fongiques au cours de l'infection par le virus de l’immunodéficience humaine. EMC - Maladies Infectieuses 2018;15:1–17. [Google Scholar]
  13. Ader F, Blanchard E, Blot M, Damien C, De Castro N, Denis B, et al. Prise en charge des complications infectieuses associées à l'infection par le VIH. HAS [Internet]. [cité 20 mars 2025]; Disponible sur: https://www.has-sante.fr/upload/docs/application/pdf/2024-07/reco484_recommandations_vih_complications_cd_20240627_pd_ap.pdf. [Google Scholar]
  14. Chandrakala C, Parimalam K, Wahab A, Anand N. Correlating CD4 count with mucocutaneous manifestations in HIV-positive patients: A prospective study. Indian J Sex Transm Dis AIDS 2017,38:128. [Google Scholar]
  15. Vohra P, Jamatia K, Subhada B, Tiwari RC, Althaf MN, Jain C. Correlation of CD4 counts with oral and systemic manifestations in HIV patients. J Fam Med Prim Care 2019, 8: 3247. [Google Scholar]
  16. Schwarcz L, Chen MJ, Vittinghoff E, Hsu L, Schwarcz S. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS 2013;27:597–605. [Google Scholar]
  17. Blanc A, Bonnet F, Bordeaux C, Brun-Vezinet F, Bernard CBC, Costagliola D, et al. Prise en charge médicale des personnes vivant avec le VIH Cancers (août 2017) [Internet. [cité 20 mars 2025]; Disponible sur: https://cns.sante.fr/sites/cns-sante/files/2017/10/experts-vih_cancers.pdf. [Google Scholar]
  18. Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, et al. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol 2014;50:1169–1176. [Google Scholar]
  19. Petersen PE. Policy for prevention of oral manifestations in HIV/AIDS: the approach of the WHO global oral health program. Adv Dent Res 2006;19:17–20. [Google Scholar]
  20. Arribas JR, Hernández-Albujar S, González-García JJ, Peña JM, Gonzalez A, Cañedo T, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis: AIDS 2000;14:979–985. [Google Scholar]
  21. Benslama L, Hasni W. Manifestations stomatologiques et maxillofaciales de l'infection par le virus de l’immunodéficience humaine. EMC - Chirurgie Orale et maxillo-faciale 2019;14:1–16. [Google Scholar]
  22. Blanc A, Bonnet F, Bordeaux C, Brun-Vezinet F, Bernard CBC, Costagliola D, et al. Prise en charge médicale des personnes vivant avec le VIH - Optimisation d'un traitement antirétroviral en situation de succès virologique (juillet 2017) [Internet. [cité 20 mars 2025]; Disponible sur: https://www.cns.sante.fr/sites/cns-sante/files/2017/01/experts-vih_optimisation.pdf. [Google Scholar]
  23. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014;14:281–290. [Google Scholar]
  24. Rouzioux C. Traiter tôt l'infection à VIH : Pourquoi? Bull Académie Natl Médecine 2018;202:1413–1420. [Google Scholar]
  25. Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. The Lancet 2007;370:59–67. [Google Scholar]
  26. King MD, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002;34:641–648. [Google Scholar]
  27. Schouten J, Wit FW, Stolte IG, Kootstra NA, Van Der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014;59:1787–1797. [Google Scholar]
  28. Johnson NW, Anaya-Saavedra G, Webster-Cyriaque J. Viruses and oral diseases in HIV-infected individuals on long-term antiretroviral therapy: What are the risks and what are the mechanisms? Oral Dis 2020;26:80–90. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.